Literature DB >> 22915184

[Adjuvant radiochemotherapy of uterine carcinosarcoma in need of optimization].

P Jiang1, S Marnitz.   

Abstract

Entities:  

Year:  2012        PMID： 22915184     DOI： 10.1007/s00066-012-0166-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.

Authors:  Mark H Einstein; Merieme Klobocista; June Y Hou; Stephen Lee; Subhakar Mutyala; Keyur Mehta; Laura L Reimers; Dennis Y-S Kuo; Gloria S Huang; Gary L Goldberg
Journal:  Gynecol Oncol       Date:  2011-11-03       Impact factor: 5.482

Review 2.  Role of radiotherapy treatment of uterine sarcoma.

Authors:  Sagus Sampath; David K Gaffney
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2011-07-23       Impact factor: 5.237

3.  Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).

Authors:  R E N van Rijswijk; J B Vermorken; N Reed; G Favalli; C Mendiola; F Zanaboni; G Mangili; I Vergote; J P Guastalla; W W ten Bokkel Huinink; A J Lacave; H Bonnefoi; S Tumulo; R Rietbroek; I Teodorovic; C Coens; S Pecorelli
Journal:  Eur J Cancer       Date:  2003-03       Impact factor: 9.162

4.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

Authors:  N S Reed; C Mangioni; H Malmström; G Scarfone; A Poveda; S Pecorelli; S Tateo; M Franchi; J J Jobsen; C Coens; I Teodorovic; I Vergote; J B Vermorken
Journal:  Eur J Cancer       Date:  2008-04-02       Impact factor: 9.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.